BNT162b2 Vaccination during Pregnancy Protects Both the Mother and Infant: Anti-SARS-CoV-2 S Antibodies Persistently Positive in an Infant at 6 Months of Age
Vaccinations are the most important intervention for controlling the ongoing coronavirus disease (COVID-19) pandemic, caused by the SARS-CoV-2 virus. BNT162b2 is an mRNA-based vaccine, which is promising and safe for use during pregnancy, as it could help prevent SARS-CoV-2 infection and its complic...
Saved in:
Main Authors: | Chetna Mangat, Natasa Milosavljevic |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-01-01
|
Series: | Case Reports in Pediatrics |
Online Access: | http://dx.doi.org/10.1155/2021/6901131 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Anti-SARS-Cov-2 S-RBD IgG Formed after BNT162b2 Vaccination Can Bind C1q and Activate Complement
by: Anas H. A. Abu-Humaidan, et al.
Published: (2022-01-01) -
BNT162b2 COVID-19 Vaccine Induced Immune Thrombocytopenic Purpura
by: A. K. Ghosh, et al.
Published: (2022-01-01) -
Efficacy of BNT162b2 and CoronaVac in patients diagnosed with COVID-19
by: Dogan Mustafa, et al.
Published: (2023-06-01) -
Invasive bacterial infections in febrile infants younger than 3 months old after SARS-CoV-2 pandemic
by: Leire Bizkarra-Txurruka, et al.
Published: (2025-01-01) -
Proteomic and serologic assessments of responses to mRNA-1273 and BNT162b2 vaccines in human recipient sera
by: Thomas E. Hickey, et al.
Published: (2025-01-01)